Lee:JC

Home                  Research                  Lab Members                  Publications                  JC                      Links                  Internal                  Contact                 

Research meeting/JC schedule 2 - 3:30 pm, every Thursday, BPC Rm 387 Date Presenter 10/14/10 (Research) Poster presentations 10/21/10 (JC) Nilay 10/28/10 (JC) Kyunghwa 11/4/10 (Research) Eun Ryoung 11/11/10 (JC) Wooin 11/18/10 (JC) Eun Ryoung 11/25/10 (No meeting) Thanksgiving 12/2/10 (JC) Kyunghwa 12/9/10 (JC) Nilay 12/16/10 (Research) Wooin Suggested future papers Whitman SP, Hackanson B, Liyanarachchi S, Liu S, Rush LJ, Maharry K, Margeson D, Davuluri R, Wen J, Witte T, Yu L, Liu C, Bloomfield CD, Marcucci G, Plass C, and Caligiuri MA. DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. Blood. 2008 Sep 1;112(5):2013-6. DOI:10.1182/blood-2008-01-128595 | Kotamraju S, Matalon S, Matsunaga T, Shang T, Hickman-Davis JM, and Kalyanaraman B. Upregulation of immunoproteasomes by nitric oxide: potential antioxidative mechanism in endothelial cells. Free Radic Biol Med. 2006 Mar 15;40(6):1034-44. DOI:10.1016/j.freeradbiomed.2005.10.052 | Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco RD, and Anderson KC. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood. 2009 Jul 30;114(5):1046-52. DOI:10.1182/blood-2009-01-199604 | Liu Y, Borchert GL, Donald SP, Diwan BA, Anver M, and Phang JM. Proline oxidase functions as a mitochondrial tumor suppressor in human cancers. Cancer Res. 2009 Aug 15;69(16):6414-22. DOI:10.1158/0008-5472.CAN-09-1223 | pmid= Past papers 2010-II Imai S, Kikuchi R, Kusuhara H, Yagi S, Shiota K, Sugiyama Y. Analysis of DNA methylation and histone modification profiles of liver-specific transporters. Mol Pharmacol. 2009 Mar;75(3):568-576 (8/3/10) Zhang L, Littlejohn JE, Cui Y, Cao X, Peddaboina C, Smythe WR. Characterization of bortezomib-adapted I-45 mesothelioma cells.Mol Cancer. 2010 May 18;9: 110(8/10/10) Kim SN, Kim NH, Lee W, Seo DW, Kim YK. Histone deacetylase inhibitor induction of P-glycoprotein transcription requires both histone deacetylase 1 dissociation and recruitment of CAAT/enhancer binding protein beta and pCAF to the promoter region. Mol Cancer Res. 2009 May;7(5):735-44 pmid=19435809 (9/16/10) Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ, Brodie AM, Edwards J, Qiu Y. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 2009 Mar 15;69(6):2305-13 pmid=19244107 (9/23/10) Maeda T, Irokawa M, Arakawa H, Kuraoka E, Nozawa T, Tateoka R, Itoh Y, Nakanishi T, and Tamai I. Uptake transporter organic anion transporting polypeptide 1B3 contributes to the growth of estrogen-dependent breast cancer. J Steroid Biochem Mol Biol 2010 Oct; 122(4) 180-5(10/7/10) van de Steeg E, Wagenaar E, van der Kruijssen CM, Burggraaff JE, de Waart DR, Elferink RP, Kenworthy KE, and Schinkel AH. Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. J Clin Invest 2010 Aug 2; 120(8) 2942-52. doi:10.1172/JCI42168 pmid:20644253 Meyer zu Schwabedissen HE, Tirona RG, Yip CS, Ho RH, Kim RB.Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer. Cancer Res. 2008 Nov 15;68(22):9338-47.PMID: 19010908 (10/28/10) 2010-I Parlati F, Lee SJ, Aujay M, Suzuki E, Levitsky K, Lorens JB, Micklem DR, Ruurs P, Sylvain C, Lu Y, Shenk KD, and Bennett MK. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood. 2009 Oct 15;114(16):3439-47. DOI:10.1182/blood-2009-05-223677 | Kuhn DJ, Hunsucker SA, Chen Q, Voorhees PM, Orlowski M, and Orlowski RZ. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood. 2009 May 7;113(19):4667-76. DOI:10.1182/blood-2008-07-171637 | Bianchi G, Oliva L, Cascio P, Pengo N, Fontana F, Cerruti F, Orsi A, Pasqualetto E, Mezghrani A, Calbi V, Palladini G, Giuliani N, Anderson KC, Sitia R, and Cenci S. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood. 2009 Mar 26;113(13):3040-9. DOI:10.1182/blood-2008-08-172734 | Ohtsuka H, Abe T, Onogawa T, Kondo N, Sato T, Oshio H, Mizutamari H, Mikkaichi T, Oikawa M, Rikiyama T, Katayose Y, and Unno M. Farnesoid X receptor, hepatocyte nuclear factors 1alpha and 3beta are essential for transcriptional activation of the liver-specific organic anion transporter-2 gene. J Gastroenterol. 2006 Apr;41(4):369-77. DOI:10.1007/s00535-006-1784-3 | Lü S, Yang J, Song X, Gong S, Zhou H, Guo L, Song N, Bao X, Chen P, and Wang J. Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line. J Pharmacol Exp Ther. 2008 Aug;326(2):423-31. DOI:10.1124/jpet.108.138131 | Muñoz MJ, Pérez Santangelo MS, Paronetto MP, de la Mata M, Pelisch F, Boireau S, Glover-Cutter K, Ben-Dov C, Blaustein M, Lozano JJ, Bird G, Bentley D, Bertrand E, and Kornblihtt AR. DNA damage regulates alternative splicing through inhibition of RNA polymerase II elongation. Cell. 2009 May 15;137(4):708-20. DOI:10.1016/j.cell.2009.03.010 | Vavricka SR, Jung D, Fried M, Grützner U, Meier PJ, and Kullak-Ublick GA. The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3beta in hepatocellular carcinoma. J Hepatol. 2004 Feb;40(2):212-8. DOI:10.1016/j.jhep.2003.10.008 | Yasuda H, Hirata S, Inoue K, Mashima H, Ohnishi H, and Yoshiba M. Involvement of membrane-type bile acid receptor M-BAR/TGR5 in bile acid-induced activation of epidermal growth factor receptor and mitogen-activated protein kinases in gastric carcinoma cells. Biochem Biophys Res Commun. 2007 Mar 2;354(1):154-9. DOI:10.1016/j.bbrc.2006.12.168 | Fuchs D, Berges C, Opelz G, Daniel V, and Naujokat C. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells. J Cell Biochem. 2008 Jan 1;103(1):270-83. DOI:10.1002/jcb.21405 | 2009-II Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, Scheffer GL, Debipersad K, Vojtekova K, Lemos C, van der Heijden JW, Ylstra B, Peters GJ, Kaspers GL, Dijkmans BA, Scheper RJ, and Jansen G. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood. 2008 Sep 15;112(6):2489-99. DOI:10.1182/blood-2007-08-104950 | Sloss CM, Wang F, Liu R, Xia L, Houston M, Ljungman D, Palladino MA, and Cusack JC Jr. Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells. Clin Cancer Res. 2008 Aug 15;14(16):5116-23. DOI:10.1158/1078-0432.CCR-07-4506 | Voortman J, Checińska A, and Giaccone G. The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells. Mol Cancer. 2007 Nov 17;6:73. DOI:10.1186/1476-4598-6-73 | Platzer B, Richter S, Kneidinger D, Waltenberger D, Woisetschläger M, and Strobl H. Aryl hydrocarbon receptor activation inhibits in vitro differentiation of human monocytes and Langerhans dendritic cells. J Immunol. 2009 Jul 1;183(1):66-74. DOI:10.4049/jimmunol.0802997 | Shabek N, Herman-Bachinsky Y, and Ciechanover A. Ubiquitin degradation with its substrate, or as a monomer in a ubiquitination-independent mode, provides clues to proteasome regulation. Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):11907-12. DOI:10.1073/pnas.0905746106 | Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, and Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 2002 Jun 15;62(12):3387-94. Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N, Gielen J, Merville MP, and Bours V. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene. 2003 Jan 9;22(1):90-7. DOI:10.1038/sj.onc.1206056 | Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA, and Orlowski RZ. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007 Nov 1;110(9):3281-90. DOI:10.1182/blood-2007-01-065888 | Khan MA, Oubrahim H, and Stadtman ER. Inhibition of apoptosis in acute promyelocytic leukemia cells leads to increases in levels of oxidized protein and LMP2 immunoproteasome. Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11560-5. DOI:10.1073/pnas.0404101101 | Xu M, Skaug B, Zeng W, and Chen ZJ. A ubiquitin replacement strategy in human cells reveals distinct mechanisms of IKK activation by TNFalpha and IL-1beta. Mol Cell. 2009 Oct 23;36(2):302-14. DOI:10.1016/j.molcel.2009.10.002 | Comerford KM, Cummins EP, and Taylor CT. c-Jun NH2-terminal kinase activation contributes to hypoxia-inducible factor 1alpha-dependent P-glycoprotein expression in hypoxia. Cancer Res. 2004 Dec 15;64(24):9057-61. DOI:10.1158/0008-5472.CAN-04-1919 | 2009-I Fang C, Dean J, and Smith JW. A novel variant of ileal bile acid binding protein is up-regulated through nuclear factor-kappaB activation in colorectal adenocarcinoma. Cancer Res. 2007 Oct 1;67(19):9039-46. DOI:10.1158/0008-5472.CAN-06-3690 | Gomes AV, Young GW, Wang Y, Zong C, Eghbali M, Drews O, Lu H, Stefani E, and Ping P. Contrasting proteome biology and functional heterogeneity of the 20 S proteasome complexes in mammalian tissues. Mol Cell Proteomics. 2009 Feb;8(2):302-15. DOI:10.1074/mcp.M800058-MCP200 | Gui C and Hagenbuch B. Amino acid residues in transmembrane domain 10 of organic anion transporting polypeptide 1B3 are critical for cholecystokinin octapeptide transport. Biochemistry. 2008 Sep 2;47(35):9090-7. DOI:10.1021/bi8008455 | Iorns E, Lord CJ, and Ashworth A. Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization. Biochem J. 2009 Jan 1;417(1):361-70. DOI:10.1042/BJ20081682 | Inoue S, Nakase H, Matsuura M, Mikami S, Ueno S, Uza N, and Chiba T. The effect of proteasome inhibitor MG132 on experimental inflammatory bowel disease. Clin Exp Immunol. 2009 Apr;156(1):172-82. DOI:10.1111/j.1365-2249.2008.03872.x | Itahana K, Mao H, Jin A, Itahana Y, Clegg HV, Lindström MS, Bhat KP, Godfrey VL, Evan GI, and Zhang Y. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell. 2007 Oct;12(4):355-66. DOI:10.1016/j.ccr.2007.09.007 | Cohen AA, Geva-Zatorsky N, Eden E, Frenkel-Morgenstern M, Issaeva I, Sigal A, Milo R, Cohen-Saidon C, Liron Y, Kam Z, Cohen L, Danon T, Perzov N, and Alon U. Dynamic proteomics of individual cancer cells in response to a drug. Science. 2008 Dec 5;322(5907):1511-6. DOI:10.1126/science.1160165 | Zheng FF, Kuduk SD, Chiosis G, Münster PN, Sepp-Lorenzino L, Danishefsky SJ, and Rosen N. Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases. Cancer Res. 2000 Apr 15;60(8):2090-4. Cohen L, Henzel WJ, and Baeuerle PA. IKAP is a scaffold protein of the IkappaB kinase complex. Nature. 1998 Sep 17;395(6699):292-6. DOI:10.1038/26254 | Rothwarf DM, Zandi E, Natoli G, and Karin M. IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. Nature. 1998 Sep 17;395(6699):297-300. DOI:10.1038/26261 | Kravtsova-Ivantsiv Y, Cohen S, and Ciechanover A. Modification by single ubiquitin moieties rather than polyubiquitination is sufficient for proteasomal processing of the p105 NF-kappaB precursor. Mol Cell. 2009 Feb 27;33(4):496-504. DOI:10.1016/j.molcel.2009.01.023 | Shah K, Liu Y, Deirmengian C, and Shokat KM. Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates. Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3565-70. DOI:10.1073/pnas.94.8.3565 | Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, Roskams T, Trautwein C, and Pasparakis M. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell. 2007 Feb;11(2):119-32. DOI:10.1016/j.ccr.2006.12.016 | Tong JK, Hassig CA, Schnitzler GR, Kingston RE, and Schreiber SL. Chromatin deacetylation by an ATP-dependent nucleosome remodelling complex. Nature. 1998 Oct 29;395(6705):917-21. DOI:10.1038/27699 | Yang Z, Gagarin D, St Laurent G 3rd, Hammell N, Toma I, Hu CA, Iwasa A, and McCaffrey TA. Cardiovascular inflammation and lesion cell apoptosis: a novel connection via the interferon-inducible immunoproteasome. Arterioscler Thromb Vasc Biol. 2009 Aug;29(8):1213-9. DOI:10.1161/ATVBAHA.109.189407 | Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, and Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004 Sep 23;431(7007):461-6. DOI:10.1038/nature02924 | Wang YD, Chen WD, Wang M, Yu D, Forman BM, and Huang W. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology. 2008 Nov;48(5):1632-43. DOI:10.1002/hep.22519 | Nakagawa H, Tamura A, Wakabayashi K, Hoshijima K, Komada M, Yoshida T, Kometani S, Matsubara T, Mikuriya K, and Ishikawa T. Ubiquitin-mediated proteasomal degradation of non-synonymous SNP variants of human ABC transporter ABCG2. Biochem J. 2008 May 1;411(3):623-31. DOI:10.1042/BJ20071229 | Kimura Y, Yashiroda H, Kudo T, Koitabashi S, Murata S, Kakizuka A, and Tanaka K. An inhibitor of a deubiquitinating enzyme regulates ubiquitin homeostasis. Cell. 2009 May 1;137(3):549-59. DOI:10.1016/j.cell.2009.02.028 | Yi F and Regan L. A novel class of small molecule inhibitors of Hsp90. ACS Chem Biol. 2008 Oct 17;3(10):645-54. DOI:10.1021/cb800162x |